Gene Interaction Network Analysis in Multiple Myeloma Detects Complex Immune Dysregulation Associated With Shorter Survival
Source : https://www.nature.com/articles/s41408-023-00935-2
The plasma cell cancer multiple myeloma (MM) varies significantly in genomic characteristics, response to therapy, and long-term prognosis. To investigate global interactions in MM, we combined a known protein interaction...
These results confirmed fidelity with known genomic risk factors as well as emerging factors not yet in clinical use.
Real-World Multiple Myeloma Risk Factors and Outcomes by Non-Hispanic Black/African American and Non-Hispanic White Race/Ethnicity in the United States
Source : https://haematologica.org/article/view/haematol.2023.282788
Examination of the impact of race and ethnicity on multiple myeloma (MM) outcomes has yielded inconsistent results. This retrospective, real-world (RW) study describes patient, disease, and treatment characteristics (and associations...
In general, associations between risk factors for rwPFS and rwOS were consistent between races/ethnicities.
Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future
Source : https://www.mdpi.com/1422-0067/24/21/15674
The landscape of therapeutic measures to treat multiple myeloma has undergone a seismic shift since the dawn of the current century. This has been driven largely by the introduction of...
Lipid Metabolic Vulnerabilities of Multiple Myeloma
Source : https://link.springer.com/article/10.1007/s10238-023-01174-2
Multiple myeloma (MM) is the second most common hematological malignancy worldwide, characterized by abnormal proliferation of malignant plasma cells within a tumor-permissive bone marrow microenvironment. Metabolic dysfunctions are emerging as...
Understanding the oncogenic mechanisms of lipid metabolism and targeting lipid metabolism reprogramming to identify new MM dependencies have important scientific significance.
Recent Advances in Cellular Immunotherapy for Lymphoid Malignancies
Source : https://pubmed.ncbi.nlm.nih.gov/37964655/
Cellular immunotherapy with chimeric antigen receptor (CAR) T-cells has revolutionized the treatment of lymphoid malignancies. This review addresses the need for CAR expression in endogenous T-cells to kill tumor cells...
Researchers review the factors associated with CAR T-cell outcomes and recent efforts to employ CAR T cells in earlier lines of therapy. They discuss the value of bispecific T-cell engagers as off-the-shelf products with improved toxicity profiles.